Your opportunity to help reach
a world without cancer.
Welcome to the ACRF Accelerate program, a unique philanthropic opportunity for donors to evaluate and contribute towards promising cancer research projects.
To help you assess the funding opportunities available, the ACRF model for impact has been developed to articulate the anticipated future impact of the projects.
This model allows you to apply a similar due diligence as you would for any significant financial decision.
“We know from cancer researchers, that access to better technology and equipment is the key to significantly shifting the dial to improve the prevention, detection and treatment of all cancers. We look forward to meeting you to understand your motivations in securing a better future.”
– Kerry Strydom, ACRF CEO
The last decade has seen significant progress in understanding how the immune system can help to control cancer, resulting in the emergence of immunotherapies – treatments which use the patient’s own immune system to target cancer.
The ACRF Centre for Intravital Imaging of Niches for Cancer Immune Therapy will implement radical, new technologies to investigate and manipulate cancer-immune cell interactions with the aim of addressing a major challenge in the treatment of cancer: why some patients have a remarkable clinical response to cancer immunotherapies, while other patients do not respond.
This world-first project will engage physics and engineering talent to build two world-first Australian-designed microscopes. These will enable researchers to see deeper inside tissues at resolutions currently not possible. Deep biological insights are needed to realise the full potential of cancer immunotherapy to cure all cancers.
Despite advances in treatment, childhood cancer is a leading cause of death for children and adolescents around the world. Early detection, diagnosis and treatment is key to saving lives and reducing the tragic toll of cancer.
This project will establish the ACRF Child Cancer Liquid Biopsy program which will allow researchers and doctors to obtain accurate information about a child’s cancer in a less invasive way than a conventional (solid) biopsy.
Liquid biopsy is a type of blood test that can detect cancer cells present and circulating tumour DNA (ctNDA) in the blood. Cancer biomarkers give information about the tumour, indicate early relapse to treatment, and potentially show real-time changes in disease.
The past few decades have seen many exciting developments in genetic profiling and personalised treatments that have enabled doctors to tailor therapies. Precision medicine has transformed cancer patient prognosis. However, even as new and promising therapies are approved, clinicians and researchers know that there will inevitably be patients whose cancers do not respond to therapies, or whose tumours quickly become resistant to the new treatment.
The ACRF Program for Resolving Cancer Complexity and Therapeutic Resistance aims to shed light on how cancer cell heterogeneity impacts treatment choices and responses across a broad range of cancers.
The project aims to define how molecular aberrations contribute to cancer cell heterogeneity and drive malignant cancer. This better understanding, at a single cell level, could help uncover new, personalised therapies. These new therapies could replace or reduce some of the 684,500 chemotherapy procedures performed in Australia every year.1
Melanoma is the most dangerous form of skin cancer because if it isn’t detected early, it can spread to other organs. For that reason, early diagnosis is key to survival.
The ACRF Australian Centre of Excellence in Melanoma Imaging and Diagnosis aims to reduce the annual melanoma death toll by using sophisticated 3D imaging systems to produce whole-body scans that can be monitored over time. These scans create patient ‘avatars’, enabling melanoma to be detected earlier.
Within 3 years, the project database of 100,000 avatars will be the largest in the world.
There are more than one million people living in Australia who have survived cancer,1 many of whom require ongoing medical and psychosocial care as a result of their disease and treatment.2 As the number of cancer survivors grows, there’s an increasing need for research into best-practice holistic patient care beyond cancer itself, including changes in clinical practice to adapt to a patient’s needs long after they finish treatment.
The aim of the ACRF Oncology Alliance for the Science of Integrated Survivorship Centre is to provide an innovation space for research to develop new evidence-based survivorship therapies and guidelines.
The Centre will deliver programs to help the physical and mental health of cancer patients and survivors and reduce the risk of long-term health and mental health effects of a cancer diagnosis and subsequent treatment.
Every research grant awarded by ACRF, on behalf of our donors, has been rigorously evaluated and recommended by our esteemed Medical Research Advisory Committee. Relying solely on philanthropic donations to award grants for cancer research projects, ACRF is committed to ensuring all funding is used as effectively as possible. The process is designed to maximise cancer research outcomes.
Through ACRF you can support visionary programs that bring together expertise from research institutes across Australia.
Innovative cancer research projects depend on cutting-edge technology and capital equipment. This is what is most needed for scientists to explore progressive ideas and is therefore ACRF’s sole focus.
“As leaders in philanthropic investment, ACRF is committed to the rigour, review and assessment of the projects presented in the ACRF Accelerate program, providing you with confidence that every donation will result in real, measurable impacts for those living with cancer.”
– Tom Dery AO, ACRF Chair
We invite you to explore these innovative projects and consider a meaningful contribution towards their success.
Send the Accelerate Prospectus to: